HDAC7 promotes ovarian cancer malignancy via AKT / mTOR signalling pathway
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Qi Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Ovarian Neoplasms, Proto-Oncogene Proteins c-akt, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Program, Shenzhen Healthcare Research Project.
Abstract (Originalsprache)
Ovarian cancer is of the most lethal malignancy and causes serious threat to women health worldwide. A deep understanding of molecular mechanisms underlying ovarian cancer progression is critical for the development of promising therapeutic strategies. In this study, we aimed to employ immunohistochemistry to determine the protein level of HDAC7 in patient tissues, our data showed HDAC7 levels are upregulated in tumour tissues. In addition, we also performed Kaplan–Meier survival analysis to investigate the association between HDAC7 expression and clinical prognosis, and found that HDAC7 expression was associated with poor prognosis in ovarian cancer patients. Inhibition of HDAC7 cells resulted in lower cell proliferation, invasion and colony formation. Furthermore, we also found that HDAC7 inhibition suppressed PI3K/AKT/mTOR pathway. In contrast, exogenous HDAC7 expression activated the PI3K/AKT/mTOR pathway in HDAC7 knockout cells and rescued the cell proliferation, invasion and colony formation. However, inhibition of p‐AKT induced lower cell proliferation, metastasis and colony formation abilities. In murine model, HDAC7 KO significantly decreased the tumour burden. These data indicate that HDAC7 is involved in regulation of PI3K/AKT/mTOR pathway and targeting of HDAC7 could be potential therapeutic strategy in the treatment of ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Jinan University, Guangzhou, China.
- International Cancer Center, Guangdong Key Laboratory of Genome Instability and Human Disease Prevention, Marshall Laboratory of Biomedical Engineering, Department of Biochemistry and Molecular Biology, Shenzhen Univers…
- Department of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
- Department of Gynecologic Oncology, Linyi Cancer Hospital, Linyi, China.
- Shenzhen Maternal and Child Healthcare Hospital, Shenzhen, China.
- Institute of Precision Medicine, Jining Medical University, Jining, Shandong, China.
ORCID-Profile: Xiugui Sheng
Förderung
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Program
- Shenzhen Healthcare Research Project
- Sanming Project of Medicine in Shenzen Municipality
Zitieren
APA
Feng, Q., Hao, S., Liu, X., Yan, Z., Sheng, K., Li, Y., Zhang, P., & Sheng, X. (2024). HDAC7 promotes ovarian cancer malignancy via AKT / mTOR signalling pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70120
Vancouver
Feng Q, Hao S, Liu X, Yan Z, Sheng K, Li Y, et al. HDAC7 promotes ovarian cancer malignancy via AKT / mTOR signalling pathway. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70120
BibTeX
@article{Feng2024,
author = {Feng, Qi and Hao, Sheng and Liu, Xiongxiu and Yan, Zhong and Sheng, Kai and Li, Yanping and Zhang, Peng and Sheng, Xiugui},
title = {HDAC7 promotes ovarian cancer malignancy via AKT / mTOR signalling pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70120}
}
EUVIMED